Replies to post #277 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

GTCB ReadMeFirst

[Updated with list of pending patent
applications and miscellaneous info
from the past two months.]


What is GTC’s business all about?
#msg-11412472 The new GTC!
#msg-11432468 FAQ
#msg-9243634 Jan 2006 interview with CEO, Geoff Cox
#msg-9352093 2002 interview with Tom Newberry (dated, but informative)
#msg-11752181 Why ATryn?
#msg-13171505 “Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the more technical reader)


Valuation and finances
#msg-12428542 Cash position and guidance
#msg-12422836 2Q06 financial results
#msg-12468464 Edited transcript from 2Q06 CC
#msg-11409187 Rodman & Renshaw $4 target
#msg-11037571 Valuation comparator: MRK paid $400M for GlycoFi
#msg-12429402 Effective share count for valuation purposes


Upcoming events
#msg-12743803 Possible/probable 2006-07 news flow


ATryn hereditary-deficiency program in Europe
#msg-11399356 ATryn approved by EMEA
#msg-11399033 ATryn Q&A from the EMEA
#msg-12399714 EU Commission clears ATryn for marketing
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
http://iurl.biz/ec Official product label


ATryn DIC/sepsis program in Europe
#msg-8316050 Leo Pharma partnership announcement
#msg-12430822 Economics of the Leo partnership
#msg-12442744 When will GTC receive milestone payments?
#msg-12511434 Phase-3 timeline
#msg-10868317 Rationale for pursuing DIC/sepsis indication
#msg-12480268 Surprising sepsis factoids
#msg-12483101 Existing therapeutic options are weak (Xigris)


ATryn development program in U.S.
#msg-12432067 U.S. ATryn timeline
#msg-6543884 Non-availability of competing antithrombin
#msg-5607789 Efficacy endpoint is clinical DVT
#msg-5609005 Design of control arm
#msg-11410659 Likelihood of success
#msg-6632420 Patient eligibility and exclusions
#msg-11511614 Musings on a U.S. partnership


ATryn vs plasma-derived antithrombin
#msg-4372780 Risks of plasma-derived proteins
#msg-13209941 Risks of plasma-derived proteins (addendum)
#msg-7306242 Which AT will doctors prescribe?
#msg-7221666 Price and availability of commercial plasma-derived AT
#msg-11909951 Talecris Thrombate AT


Miscellaneous info on ATryn and antithrombin
#msg-13547440 Antithrombin abstracts and write-ups
#msg-9502819 A patient’s story
#msg-9819574 ATryn vs oral anticoagulants


Non-ATryn development programs
Background info: http://www.transgenics.com/products/prod.html
#msg-8163705 Merrimack program in RA
#msg-10727170 Merrimack program in psoriasis
#msg-10485655 Merrimack raises $65M to fund MM-093 program
#msg-11252196 Merrimack firms up manufacturing plans for phase-3
#msg-8111599 Musings on economics of Merrimack collaboration
#msg-7136629 Collaboration with Scancell
#msg-5054169 Human serum albumin


Intellectual property
#msg-9174865 Production (“milk”) patent
#msg-7179529 Purification patent
#msg-13154218 Nuclear-transfer IP (Geron)
#msg-4107224 IP license to Nexia (now PharmAthene/SIGA)
#msg-13681118 Pending patent applications


Competition
#msg-11829819 Talecris AAT
#msg-6488263 PurelyProteins AAT (market-size info)
#msg-13102354 Protherics CytoFab for sepsis
#msg-11910185 Milipore/Novozymes albumin
#msg-7542154 Origen’s transgenic chickens
#msg-8863527 Companies to watch (Drug Discovery & Development)


Miscellaneous topics
#msg-4787482 High-pedigreed GTC directors
#msg-4316445 ATryn research contract with U.S. army


Feature stories on GTCB and transgenics
#msg-13365243 Times of London (9/17/06)
#msg-13152292 Nature.com (9/7/06)
#msg-12573463 Nature Biotechnology (8/06)
#msg-12273566 Boston Globe profiles Dr. Harry Meade (7/06)
#msg-11635041 Framingham, MA Daily News (6/06)
#msg-9243634 Red Herring (1/06)
#msg-9143261 Business Week (1/06)
#msg-8162424 Scientific American (11/05)
#msg-6806806 Wall St Transcript interview with Tom Newberry (6/05)
#msg-6775592 Newsweek special issue on healthcare (6/05)
#msg-6276428 Worcester, MA Telegram & Gazette (5/05)
#msg-7431316 Nature Biotechnology (10/04)
#msg-4057315 The Economist (9/04)